Journal of Clinical Oncology
Articles in this Issue
Clinicopathologic features, actionable biomarkers, and treatment patterns in early-onset gastric cancer: A real-world Latin American cohort.
e23385 Background: Early-onset gastric cancer (EOGC), defined as diagnosis before age 50, is biologically aggressive and o...
The prevalence of osteopenia in adult non-metastatic gastrointestinal cancer patients: A systematic review and meta-analysis.
e23187 Background: Improvements in survival among patients with gastrointestinal (GI) cancer have led to a shift in focus...
Safety and efficacy of neoadjuvant chemotherapy (NAC) in older patients with locally advanced colon cancer (LACC): Results from FOxTROT 1 and the FOxTROT 2 safety cohort population.
3653 Background: The FOxTROT1 (FT1; NCT00647530) trial demonstrated feasibility and efficacy of six weeks of NAC for LACC...
Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) for resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Efficacy by surgical outcomes in the phase 3 KEYNOTE-689 trial.
6057 Background: In the phase 3 KEYNOTE-689 trial (NCT03765918), neoadjuvant and adjuvant pembro plus SOC (surgery and pos...
Racial disparities in stage at diagnosis of HIV–associated cancers: A SEER Analysis 2018-2022.
e13733 Background: Cancer risk is increased in people living with HIV (PLWH), and malignancy forms a leading cause of morb...
ALKOVE-1: Efficacy and safety of neladalkib in patients with advanced <i>ALK</i> + NSCLC.
8503 Background: Neladalkib is an investigational ALK TKI designed for inhibition of ALK single and compound resistance mu...
Stereotactic body radiotherapy (SBRT) combined with PD-1 inhibitor and chemotherapy in early-stage treatment-naive triple-negative breast cancer patients: A multicenter phase III clinical study.
TPS657 Background: Early-stage triple-negative breast cancer (TNBC) carries a high risk of locoregional recurrence and dis...
Second locoregional recurrence (LRR) in hormone receptor (HR)+/HER2- breast cancer (BC).
e12537 Background: Evidence regarding the treatment and prognosis of patients with HR+/HER2- BC who experience a second co...
Trends and disparities in mortality related to malignant genital neoplasms in the United States, 1999-2023.
e23361 Background: Malignant genital neoplasms in both men and women markedly elevate mortality risk, as tumor progression...
Safety and feasibility of cabozantinib (CABO) in combination with cisplatin, doxorubicin, and high-dose methotrexate (MAP) in patients with newly diagnosed high-risk osteosarcoma (OS).
10030 Background: CABO is a multi-targeted kinase inhibitor of VEGFR2, c-MET, AXL and RET and has shown clinical evidence...
Survival outcomes of plasmablastic lymphoma according to immune status.
7088 Background: Plasmablastic lymphoma (PBL) is a rare, aggressive subtype of NHL associated with HIV, but also reported...
Phase II RAINSPOT: A multicentric open label trial of zolbetuximab-paclitaxel-ramucirumab in second-line setting for CLDN18.2-positive gastro-esophageal adenocarcinoma.
TPS4243 Background: Claudin 18.2 (CLDN18.2) is an emerging therapeutic biomarker in gastro-oesophageal adenocarcinoma. Pha...
Clinicopathologic characteristics and treatment outcomes of advanced high-grade serous ovarian cancer in Pakistan: A single-center study.
e17553 Background: High-grade serous ovarian carcinoma (HGSC) is the most lethal subtype of ovarian cancer. Evidence from...
Correlation between dual FDG/PSMA PET mismatch and ctDNA genomic profiling in metastatic castration-resistant prostate cancer (mCRPC) patients screened for 177Lu-PSMA.
5067 Background: 177Lu-PSMA radioligand therapy is now a standard treatment for patients (pts) with mCRPC. Dual-tracer FDG...
FGF4-mediated resistance to combined anti-angiogenic and immunotherapy in esophageal squamous cell carcinoma via suppression of high endothelial venules and tertiary lymphoid structure formation.
4077 Background: Many patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC) fail to achieve a pathol...
First-in-human phase 1a/1b study of LB-LR1109, an anti-LILRB1 monoclonal antibody, as monotherapy in advanced solid tumors and in combination with atezolizumab in advanced NSCLC.
TPS2668 Background: LB-LR1109 is a human IgG4 monoclonal antibody targeting LILRB1, an inhibitory receptor expressed on mu...
Neoadjuvant chemotherapy with or without radiation versus upfront esophagectomy in small cell carcinoma of the esophagus: A national database analysis of overall survival.
e16126 Background: Small cell carcinoma of the esophagus (SCCE) is a rare malignancy characterized by aggressive biology,...
Patterns of health information seeking and digital health engagement in adults with cardiovascular disease and cancer.
e13716 Background: Adults living with both cardiovascular disease (CVD) and cancer represent a high-risk and understudied...
Comparative effectiveness of radical surgery versus concurrent chemoradiotherapy in stage IB3, IIA2, or iiiCr cervical cancer: A prospective, multicenter, propensity score–matched cohort study.
e17503 Background: While concurrent chemoradiotherapy (CCRT) is the standard first-line treatment, radical surgery (RS) is...
Update results of benmelstobart (BEN) combined with concurrent chemoradiotherapy (cCRT) versus cCRT alone as neoadjuvant therapy for esophageal squamous cell carcinoma (ESCC): A multicentre, randomised study.
e16112 Background: Standard neoadjuvant concurrent chemoradiotherapy (cCRT) for resectable ESCC yields only a 20-30% patho...
Final results and preliminary correlative analysis of a phase I study of anetumab ravtansine in combination with checkpoint inhibitors and gemcitabine in mesothelin-positive advanced pancreatic adenocarcinoma (NCI10208).
4205 Background: Anetumab-ravtansine (AR) is an ADC composed of IgG1 targeting the protein mesothelin (MSLN) linked to DM4...
Cancer-associated myocarditis outside of immunotherapy: National burden and inpatient outcomes in the National Inpatient Sample, 2018–2023.
e23218 Background: Immune checkpoint inhibitor myocarditis is increasingly recognized in oncology, yet myocarditis occurri...
Clinical and translational analysis of a phase Ib/II combination of atezolizumab, cobimetinib, and eribulin (ACE) to demonstrate inflammatory and metabolic programs define divergent response states.
1138 Background: Inflammatory breast cancer (IBC) is a rare, aggressive subtype with poor outcomes and limited immunothera...
A phase 1/2, first-in-human study of AVZO-021, a selective cyclin-dependent kinase 2 inhibitor (CDK2i), as monotherapy and in combination for patients with advanced solid tumors, including hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2−) breast cancer (BC) and cyclin E1 (CCNE1)–amplified solid tumors: Updated safety and efficacy results.
1094 Background: AVZO-021 is a potent, once-daily, oral CDK2i with high selectivity against CDK1, thus minimizing off-targ...
Female cancer patterns and treatment disparities in southeastern Pará, Brazilian Amazon.
e13115 Background: Cancer disparities disproportionately affect women living in socio-environmentally vulnerable regions o...